Session

Back to Programme Overview

Epigenetics and novel signaling pathways in prostate carcinogenesis

Poster Session 07

  • Location:
    Room Amsterdam, North Hall (Level 1)
  • Chairs:
     C.P. Evans, Sacramento (US)
     G. Jenster, Rotterdam (NL)
     S. Perner, Luebeck (DE)
  • Aims and objectives of this session

    Invasion and metastasis in prostate cancer are regulated by different signaling molecules. In this session, the pathway of Wnt/beta-catenin and its interaction with other signaling cascased in prostate tumorigenesis and progression will be highlighted. In addition, novel findings about regulation of the key transcription factor ERG will be presented.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
90
The prostate cancer-bone environment causes upregulation of the pentose phosphate pathway

By: Whitburn J.1, Rao S.1, Tabata S.2, Hirayama A.2, Soga T.2, Hamdy F.1, Edwards C.1

Institutes: 1University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, 2Keio University, Institute for Advanced Biosciences, Tsuruoka, Japan

91
A novel epigenetic crosstalk between ERG and EZH2 leads to prostate cancer progression

By: Zoma M.1, Curti L.1, Shinde D.1, Mitra A.1, Albino D.1, Rossi S.1, Civenni G.1, Losa M.1, Thalmann G.2, Chiorino G.3, Catapano C.V.1, Carbone G.M.1

Institutes: 1IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, 2University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland, 3Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy

92
Stage-specific embryonal antigen 4 expressing human prostate stem cells have enhanced regenerative potential in vivo

By: Höfner T.1, Klein C.2, Eisen C.2, Rigo-Watermeier T.2, Haferkamp A.1, Sprick M.2

Institutes: 1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2Heidelberg Institute for Stem Cell Technology and Experimental Medicine, HI-STEM GGmbH, Heidelberg, Germany

93
Cell surface GRP78 activation by anti-GRP78 autoantibodies confers prostate tumour growth via tissue factor activation

By: Al-Hashimi A., Hoogenes J., Shayegan B., Austin R.

Institutes: McMaster University, Dept. of Medicine, Hamilton, Canada

94
MALT1 is a downstream gene of WNT/β-catenin inducing cell proliferation and invasion potential via the upregulation of NFκB activity in human prostate carcinoma cells

By: Juang H-H.1, Tsui K-H.2

Institutes: 1Chang Gung University, Dept. of Anatomy, Tao-yuan, Kwei-shan, Taiwan, 2Chang Gung Memorial Hospital, Dept. of Urology, Tao-yuan, Kwei-shan, Taiwan

95
SE-cadherin stimulates integrin-mediated chemotaxis in prostate cancer

By: Tsaur I.1, Maxeiner S.2, Rutz J.2, Thomas C.1, Jüngel E.1, Haferkamp A.1, Blaheta R.A.2

Institutes: 1University Medicine Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, 2University Hospital Frankfurt, Dept. of Urology and Pediatric Urology, Frankfurt, Germany

* 96
Compartmentalized δ-catenin driven by genomic rearrangement in prostate cancer dictates growth factor dependent, intratumoral cell fate and behavior

By: Lu Q.1, Li M-C.1, Zhang J.2, Chen Y-H.2, Boykins C.1, Du J.3, Ai X.5, Chen B-A.6, Jiang Y-G.4

Institutes: 1Brody School Of Medicine At East Carolina University, Dept. of Anatomy and Cell Biology, Greenville, United States of America, 2Brody School Of Medicine At East Carolina University, Dept. of Anatomy And Cell Biology, Greenville, United States of America, 3Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing An Zhen Hospital, Capital Medical University, Beijing, China, 4Beijing An Zhen Hospital, Capital Medical University, Dept. of Urology, Beijing, China, 5PLA Army General Hospital, Dept. of Urology, Beijing, China, 6Southeast University School of Clinical Medicine, Dept. of Hematology and Oncology, Nanjing, China

97
Expression of checkpoint receptors in tumor-infiltrated T-cells of renal cell and prostate carcinomas

By: Bedke J.1, Zelba H.2, Hennenlotter J.1, Zettl M.3, Rammensee H-G.2, Stenzl A.1, Gouttefangeas C.2

Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2University of Tübingen, Dept. of Immunology, Tübingen, Germany, 3Boehringer Ingelheim RCV GmgH & CoKG, NBE Discovery, Vienna, Austria

* 98
Evaluation of systematic alterations in the proteome by androgen receptor stimulation and blockade in prostate cancer

By: Molokwu C.1, Kristensen A.2, Zhang F.3, Saxena N.3, Shrestha R.4, Bell R.4, Hach F.4, Collins C.5, Sorensen P.6, Gleave M.5

Institutes: 1Bradford Royal Infirmary, Dept. of Urology, Bradford, United Kingdom, 2British Columbia Cancer Research Centre, Proteomics Unit, Vancouver, Canada, 3Vancouver Prostate Centre, Tumour Biology Group, Vancouver, Canada, 4Vancouver Prostate Centre, Bioinformatics Group, Vancouver, Canada, 5University of British Columbia, Dept. of Urological Sciences, Vancouver, Canada, 6University of British Columbia, Dept. of Pathology & Laboratory Medicine, Vancouver, Canada

99
Description of the dimerization surface for the ligand-binding domain of the androgen receptor and its role in transcriptional control by agonists and antagonists

By: Claessens F.1, Nadal M.2, Prekovic S.1, Gallastegui N.2, Helsen C.1, Abella M.2, Zielinska K.2, Gay M.3, Vilaseca M.3, Taules M.4, Houtsmuller A.5, Van Royen M.5, Fuentes-Prior P.2, Estebanez-Perpina E.2

Institutes: 1KU Leuven, Molecular Endocrinology Laboratory, Leuven, Belgium, 2Institute of Biomedicine of The University of Barcelona, Dept. of Biochemistry and Molecular Biomedicine, Barcelona, Spain, 3Parc Cientific De Barcelona, Mass Spectrometry Core Facility, Barcelona, Spain, 4Centres Cientifics I Tecnologics, Unitat De Citometra, Barcelona, Spain, 5Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands

100
Bone morphogenic protein-6 and retinoblastoma expression: An inverse relationship in prostate cancer progression?

By: McCormick K.1, Leiblich A.1, Stevens D.1, Alves C.1, Fan S-J.1, Carr K.1, Morris J.1, Harris A.2, Wilson C.1, Hamdy F.3, Goberdhan D.1

Institutes: 1University of Oxford, Dept. of Physiology, Anatomy and Genetics, Oxford, United Kingdom, 2University of Oxford, The Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom, 3University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom

Epigenetics in prostate cancer
 G. Jenster, Rotterdam (NL)